Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Stimulants
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Stimulants
Sexuality, sexual behaviour, sexual violence
Cannabis — Stimulants
Stimulants — Comorbidity
Youth — Stimulants
Thursday, 08 August
14:05
Harm reduction response to amphetamine users
14:05
Wednesday, 23 October
10:50
Stimulants — use, harm and interventions
10:50
to
12:20
Networking zone 4 (N4)
Janusz Sieroslawski
Insights in biology
10:50
to
12:20
Insights zone 1 (I1)
Fernando Rodriguez de Fonseca
13:20
Risk behaviours in context
13:20
to
14:50
Networking zone 2 (N2)
Anja Busse
15:00
New psychoactive substances
15:00
to
16:30
Networking zone 3 (N3)
Pierluigi Simonato
16:50
Extending the evidence-base of opioid substitution treatment
16:50
to
18:20
Insights zone 4 (I4)
John Marsden
Responding to vulnerability and special needs
16:50
to
18:20
Networking zone 2 (N2)
Kerstin Stenius
Thursday, 24 October
10:50
Results from ATTUNE
Understanding pathways to stimulant use: a mixed methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe
10:50
to
12:20
Central square 2 (C2)
Marcus-Sebastian Martens
Gender perspectives
10:50
to
12:20
Central square 3 (C3)
Anne Line Bretteville-Jensen
16:50
Emerging drug trends in North Africa and Middle East
Focus on the EU borders
16:50
to
18:20
Insights zone 2 (I2)
Ioanna Yiasemi
Thomas Néfau
18:30
Challenges for harm reduction II
18:30
to
19:30
Insights zone 3 (I3)
Alessandro Pirona
Friday, 25 October
10:45
Epidemiology of infectious diseases
10:45
to
12:15
Insights zone 4 (I4)
Thomas Seyler
Therapeutic horizons II
10:45
to
12:15
Central square 1 (C1)
Felix Carvalho
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
11:00
Short communication
Do more people in Europe need treatment for problems related to cocaine use? An analysis of cocaine treatment demand in nine European countries
11:00
to
11:10
Networking zone 4 (N4)
Antoine Jérôme
Oral presentation
Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents
11:00
to
11:15
Insights zone 1 (I1)
Christian Büchel
11:10
Short communication
Psychostimulant induce neuronal plasticity by cytoskeleton remodeling via cdc42 pathway
11:10
to
11:20
Networking zone 4 (N4)
Andrea Lobo
11:15
Oral presentation
Epigenetics of drug addiction: a therapeutic opportunity and a transgenerational inheritance concern
11:15
to
11:30
Insights zone 1 (I1)
Felix Carvalho
11:30
Oral presentation
An astrocyte-microglia crosstalk mediating neuroinflammation under exposure to psychostimulants
11:30
to
11:45
Insights zone 1 (I1)
Teresa Summavielle
11:40
Short communication
Crackland in Brazil: epidemiological monitoring method and results
11:40
to
11:50
Networking zone 4 (N4)
Clarice Madruga
11:45
Oral presentation
Acute psychotropic effects of 9-tetrahydrocannabinol (THC) associated with resting state brain function in the human insula: a pharmacological MRI study
11:45
to
12:00
Insights zone 1 (I1)
Matthijs Bossong
11:50
Short communication
'I have no clue why I’m doing this' – a qualitative study on crack cocaine use in Frankfurt, Germany
11:50
to
12:00
Networking zone 4 (N4)
Bernd Werse
12:00
Oral presentation
Synthetic cannabinoids 5F-PB22 and THJ-2201 promote neuronal differentiation in neureblastoma cells at biologically relevant concentrations
12:00
to
12:15
Insights zone 1 (I1)
João Pedro Silva
13:30
Oral presentation
Substance Use Sex Index (SUSI): towards a new behaviour change assessment tool
13:30
to
13:45
Networking zone 2 (N2)
Nadine Ezard
13:45
Oral presentation
Chemsex experiences: pleasures, harms and care
13:45
to
14:00
Networking zone 2 (N2)
Maitena Milhet
14:00
Oral presentation
The counselors’ perspective on the use of methamphetamine in a sexual context among men who have sex with men
14:00
to
14:15
Networking zone 2 (N2)
Valérie Aubut
14:15
Oral presentation
Faster, higher, stronger? Results from a Belgian survey on PED use among gym-goers
14:15
to
14:30
Networking zone 2 (N2)
Bertrand Fincoeur
15:10
Short communication
Insights into benzo fury toxicity: 5-(2-aminopropyl)benzofuran and 6-(2-aminopropyl)benzofuran disrupt oxidative, energetic and mitochondrial homeostasis of hepatocytes in vitro
15:10
to
15:20
Networking zone 3 (N3)
Rita Roque Bravo
15:20
Short communication
Tracking NPS in Portugal: the case of MTMP
15:20
to
15:30
Networking zone 3 (N3)
Helena Gaspar
15:30
Short communication
Single binge dosing of 4-Methylethcathinone (4-MEC) induces sturdy and durable cognitive impairment in mice
15:30
to
15:40
Networking zone 3 (N3)
Cristina Sampayo
15:40
Short communication
Abuse potential of new psychoactive substances: N-ethylhexedrone, 4-Methylethcathinone, 4-Fluoromethcathinone and Buphedrone
15:40
to
15:50
Networking zone 3 (N3)
Cristina Sampayo
15:50
Short communication
Studies on the metabolism of synthetic cathinones N-ethylhexedrone and buphedrone using liquid chromatography-mass spectrometry (LC-MS/MS)
15:50
to
16:00
Networking zone 3 (N3)
Joana Carrola
16:00
Short communication
Changa – fist time identification in Portugal
16:00
to
16:10
Networking zone 3 (N3)
Maria João Caldeira
16:10
Short communication
Variations and determinants of novel psychoactive substance use: a mixed methods study to identify the implications for policy and practice
16:10
to
16:20
Networking zone 3 (N3)
Kathryn Higgins
17:00
Oral presentation
Socioeconomic status and parental education in vulnerability for substance use disorders
17:00
to
17:15
Networking zone 2 (N2)
Sabrina Molinaro
Oral presentation
Predictors of treatment allocation guesses in a randomised controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder
17:00
to
17:15
Insights zone 4 (I4)
Kirsten Marchand
17:15
Oral presentation
People with lifelong disability and their experiences of pubs and clubs in Australia
17:15
to
17:30
Networking zone 2 (N2)
Hannah Pitt
Oral presentation
Illicit stimulant use in the context of daily injectable opioid agonist treatment: a grounded theory study with patients receiving treatment for severe opioid use disorder in Vancouver, Canada
17:15
to
17:30
Insights zone 4 (I4)
Heather Palis
17:30
Oral presentation
Hospitalisation of children after prenatal exposure to methamphetamine
17:30
to
17:45
Networking zone 2 (N2)
Svetlana Skurtveit
Oral presentation
The effect of entry and retention in opioid substitution therapy on contact with the criminal justice system among opioid dependent people
17:30
to
17:45
Insights zone 4 (I4)
Natasa Gisev
17:45
Oral presentation
Veterans, substance use and trauma-informed care: analysis of veterans’ treatment needs in a multi-state sample of inmates
17:45
to
18:00
Networking zone 2 (N2)
Michele Pich
Oral presentation
Depot buprenorphine for opioid dependence in prisons in NSW, Australia
17:45
to
18:00
Insights zone 4 (I4)
Adrian Dunlop
18:00
Oral presentation
The association of traumatic experiences, perceived discrimination and affective symptoms with substance use among Russian and Kurdish migrants in Finland: a population-based study
18:00
to
18:15
Networking zone 2 (N2)
Essi Salama
Oral presentation
Slow release oral morphine versus methadone for the treatment of opioid use disorder: a systematic review and meta-analysis
18:00
to
18:15
Insights zone 4 (I4)
Jan Klimas
Thursday, 24 October
10:50
Oral presentation
Introduction to the European ATTUNE study: overview of aim, objectives and design of the project
10:50
to
12:20
Central square 2 (C2)
Uwe Verthein
Oral presentation
Understanding different pathways of ATS use over time: results and conclusions from in-depth qualitative interviews in five European countries
10:50
to
12:20
Central square 2 (C2)
Amy O’Donnell
Oral presentation
Motives for and consequences from ATS use: findings from a multinational survey of ATS users and non-users
10:50
to
12:20
Central square 2 (C2)
Nienke Liebregts
Oral presentation
Associations between personality traits, sensation seeking, self-efficacy, resilience and patterns of ATS use
10:50
to
12:20
Central square 2 (C2)
Magdalena Rowicka
Marcus-Sebastian Martens
Oral presentation
Impact of critical life events on ATS use trajectories
10:50
to
12:20
Central square 2 (C2)
Benjamin Petruzelka
11:00
Oral presentation
Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
11:00
to
11:15
Central square 3 (C3)
Judit Tirado-Muñoz
11:15
Oral presentation
A gendered approach to women’s lived experiences of gambling harm: preliminary findings
11:15
to
11:30
Central square 3 (C3)
Simone McCarthy
11:30
Oral presentation
How can partners influence the gambling habits of their gambler spouse?
11:30
to
11:45
Central square 3 (C3)
Melissa Cote
11:45
Oral presentation
Methamphetamine use during pregnancy and weak evidence of adverse neonatal outcomes
11:45
to
12:00
Central square 3 (C3)
Roman Gabrhelik
17:00
Oral presentation
Framing the non-medical use of tramadol in Africa- global opioid crises, medicrime or inadequate healthcare systems
17:00
to
17:20
Insights zone 2 (I2)
Axel Klein
17:20
Oral presentation
Captagon: knowns and unknows
17:20
to
17:35
Insights zone 2 (I2)
Laurent Laniel
17:35
Oral presentation
Libya’s changing drug trafficking dynamics on the coastal and desert borders
17:35
to
17:50
Insights zone 2 (I2)
Mark Micallef
17:50
Oral presentation
Harm reduction services in MENA region: Assessment of the situation and response by MENAHRA
17:50
to
18:05
Insights zone 2 (I2)
Elie Aaraj
18:05
Oral presentation
Wastewater-based drug epidemiology data in selected community compared to a forensic toxicology investigation finding. Sewage sensors towards evaluation of drug use trends
18:05
to
18:20
Insights zone 2 (I2)
Bilel Moslah
18:30
Oral presentation
Re-emergence of injecting drug use-related HIV despite a comprehensive harm reduction environment
18:30
to
18:45
Insights zone 3 (I3)
Andrew McAuley
18:45
Oral presentation
Amphetamine-type stimulant use: global and European trends in the harm reduction response
18:45
to
19:00
Insights zone 3 (I3)
Sam Shirley-Beavan
19:00
Oral presentation
Implementation of an educational intervention for safer injection in the European context: preliminary results from the EUROSIDER project
19:00
to
19:15
Insights zone 3 (I3)
Perrine Roux
Friday, 25 October
10:55
Oral presentation
Memory-focused cognitive therapy for cocaine use disorder: theory, procedures and preliminary evidence from an external pilot randomised controlled trial
10:55
to
11:10
Central square 1 (C1)
John Marsden
Oral presentation
Infectious diseases among people who inject drugs in France: the importance of acting on risk environment in an evolving crisis
10:55
to
11:10
Insights zone 4 (I4)
Marie Jauffret-Roustide
11:10
Oral presentation
Treatment of youth with substance use disorder and co-existing mental disorder: the MOVE programme.
11:10
to
11:25
Central square 1 (C1)
Mads Uffe Pedersen
Oral presentation
Pakistan’s heterogeneous HIV epidemic in people who inject drugs: identifying key contributing factors
11:10
to
11:25
Insights zone 4 (I4)
Aaron Lim
11:25
Oral presentation
The impact of maternal alexithymia on parenting behaviours in the context of substance use disorders
11:25
to
11:40
Central square 1 (C1)
Alessio Porreca
Oral presentation
Modelling HIV transmission amongst high-risk groups to determine the extent that HIV transmission is driven by key populations and risk behaviours in Tijuana, Mexico
11:25
to
11:40
Insights zone 4 (I4)
Hannah Fraser
11:40
Oral presentation
The role of social environment in pathways to recovery: a scoping review
11:40
to
11:55
Central square 1 (C1)
João Pedro Ramos
Oral presentation
Characteristics of polydrug use and associations with HIV risk behaviours among people who inject drugs in two cities in Europe
11:40
to
11:55
Insights zone 4 (I4)
Isabel Tavitian-Exley
11:55
Oral presentation
Modelling the impact of prevention and treatment interventions on HIV and Hepatitis C virus transmission among PWID in Nairobi
11:55
to
12:10
Insights zone 4 (I4)
Jack Stone
Hannah Fraser